US2007172532A1PendingUtilityA1
Complex Mixtures Exhibiting Selective Inhibition of Cyclooxygenase-2
Est. expiryJun 20, 2021(expired)· nominal 20-yr term from priority
A61P 9/00A61P 37/08A61P 3/10A61P 43/00A61P 9/10A61P 7/06A61P 37/02A61P 25/04A61P 25/00A61P 29/00A61P 25/06A61P 31/12A61P 25/28A61P 31/04A61P 35/00A61P 27/02A61P 19/02A61K 31/12A61P 11/02A61P 1/04A61K 45/06A61P 17/02A61K 31/00A61P 13/12A61P 17/00A61P 1/02A61P 11/06A61P 21/00A23L 33/10A61P 11/00A61P 21/04
58
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A novel formulation is provided that serves to specifically inhibit the COX-2 mediated inflammatory response in animals. The formulation comprises an effective amount of component I selected from the group consisting of alpha acids and beta acids and an effective amount of at least one component II selected from the group consisting of alpha acids, beta acids, essential oils, fats and waxes, with the proviso that component I and II are not the same compound. The composition provides specific inhibition of cyclooxygenase-2 with little or no effect on cyclooxygenase-1.
Claims
exact text as granted — not AI-modified1 . A composition comprising a pharmaceutical grade extract of hops comprising an effective amount of tetrahydroisohumulone and an effective amount of at least one component selected from the group consisting of essential oils, fats and waxes, wherein said pharmaceutical grade extract provides about 0.5 to 100 mg per kg of body weight per day of tetrahydroisohumulone.
2 . A composition comprising a pharmaceutical grade extract of hops comprising an effective amount of tetrahydroisohumulone and an effective amount of at least one component selected from the group consisting of essential oils, fats and waxes, wherein said pharmaceutical grade extract provides 10 to 95 weight % of tetrahydroisohumulone of the composition.
3 . The composition according to claims 1 or 2 , further comprising a pharmaceutical acceptable carrier selected from the group consisting of coatings, isotonic and absorption delaying agents, binders and adhesives, lubricants, disintegrants, coloring agents, flavoring agents, sweetening agents, absorbants, detergents, and emulsifying agents.
4 . The composition according to claims 1 or 2 , further comprising a member selected from the group consisting of antioxidants, vitamins and minerals.
5 . The composition according to claims 1 or 2 , further comprising a member selected from the group consisting of proteins, fats, carbohydrates, glucosamine, chondroitin sulfate and amino sugars.
6 . A dosage form of a pharmaceutical grade extract of hops comprising an effective amount of tetrahydroisohumulone and an effective amount of at least one component selected from the group consisting of essential oils, fats, and waxes, wherein said pharmaceutical grade extract provides about 0.5 to 100 mg per kg of body weight per day of tetrahydroisohumulone.
7 . A dosage form of a pharmaceutical grade extract of hops comprising an effective amount of tetrahydroisohumulone and an effective amount of at least one component selected from the group consisting of essential oils, fats, and waxes, wherein said pharmaceutical grade extract provides 10 to 95 weight % of tetrahydroisohumulone of the composition.
8 . The dosage form according to claims 6 or 7 , wherein said dosage form is a capsule, powder, tablet, injectable suspension, spray solution, spray suspension, or lotion.
9 . The dosage form according to claims 6 or 7 , further comprising a pharmaceutical acceptable carrier selected from the group consisting of coatings, isotonic and absorption delaying agents, binders and adhesives, lubricants, disintegrants, coloring agents, flavoring agents, sweetening agents, absorbants, detergents, and emulsifying agents.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.